Toujeo is a long-acting form of insulin. It works by lowering the level of blood sugar in the body. It is not used for diabetic ketoacidosis. Toujeo is given as a subcutaneous injection. For ...
BRIDGEWATER, N.J., Nov. 4, 2019 /PRNewswire/ -- Children and adolescents (aged 6 to 17 years) living with type 1 diabetes achieved comparable reduction in average blood sugar (HbA 1c) and similar risk ...
The U.S. Food and Drug Administration has approved Sanofi's diabetes drug Toujeo (insulin glargine injection, 300 U/mL). The drug is a once-daily long-acting basal insulin indicated to improve ...
PARIS, Feb. 25, 2015 /PRNewswire-USNewswire/ -- Sanofi announced today that the U.S. Food and Drug Administration (FDA) approved Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL), a ...
PARIS, June 14, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that, in a pooled analysis, investigational therapy Toujeo ® (insulin glargine [rDNA origin] injection, 300 ...
- In EDITION JP I and II, investigational Toujeo ® demonstrated similar blood sugar control with fewer night-time low blood sugar events over 6-month study period, vs. Lantus ® - Sanofi (EURONEXT : ...
- In EDITION JP I and II, investigational Toujeo(R)demonstrated similar blood sugar control with fewer night-time low blood sugar events over 6-month study period, vs. Lantus(R)- Sanofi announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback